{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:26:12Z","timestamp":1792524372195,"version":"4.5.0"},"reference-count":100,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["bprclinrheum.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.berh.2014.10.011","type":"journal-article","created":{"date-parts":[[2014,11,22]],"date-time":"2014-11-22T12:32:50Z","timestamp":1416659570000},"page":"793-806","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs"],"prefix":"10.1016","volume":"28","author":[{"given":"Enrique Roberto","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Laura","family":"Acosta-Felquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phat","family":"Luong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liron","family":"Caplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2014.10.011_bib1","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A\u00a0systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib2","first-page":"472","article-title":"Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs \u2013 comparison of drugs and adverse reactions","volume":"35","author":"Helliwell","year":"2008","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1007\/s11926-009-0038-9","article-title":"Update on the treatment of peripheral arthritis in psoriatic arthritis","volume":"11","author":"Soriano","year":"2009","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.berh.2014.10.011_bib4","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/ard.2007.072652","article-title":"A\u00a0systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis","volume":"67","author":"Ravindran","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib5","first-page":"1422","article-title":"Therapies for peripheral joint disease in psoriatic arthritis. A systematic review","volume":"33","author":"Soriano","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib6","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1093\/rheumatology\/kes001","article-title":"A\u00a0randomized placebo-controlled trial of methotrexate in psoriatic arthritis","volume":"51","author":"Kingsley","year":"2012","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib7","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3899\/jrheum.120248","article-title":"The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis","volume":"89","author":"Soriano","year":"2012","journal-title":"J\u00a0Rheumatol Suppl"},{"key":"10.1016\/j.berh.2014.10.011_bib8","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1136\/ard.2008.094946","article-title":"Treatment recommendations for psoriatic arthritis","volume":"68","author":"Ritchlin","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib9","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1002\/art.22379","article-title":"Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial","volume":"56","author":"Gladman","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib10","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1136\/annrheumdis-2013-204902","article-title":"Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study)","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib11","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1002\/art.22805","article-title":"Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2","volume":"56","author":"van der Heijde","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib12","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2012-202347","article-title":"The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study","volume":"73","author":"Fagerli","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib13","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/annrheumdis-2013-203696","article-title":"Effect of certolizumab pegol on signs and symptoms in patients with psoriatic arthritis: 24-week results of a phase 3 double-blind randomised placebo-controlled study (RAPID-PsA)","volume":"73","author":"Mease","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib14","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1136\/annrheumdis-2012-203018","article-title":"Switching between TNF inhibitors in psoriatic arthritis: data from the NOR-DMARD study","volume":"72","author":"Fagerli","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib15","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1002\/art.37876","article-title":"Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor alpha inhibitor therapy: results from the Danish Nationwide DANBIO Registry","volume":"65","author":"Glintborg","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib16","doi-asserted-by":"crossref","first-page":"R29","DOI":"10.1186\/ar1881","article-title":"Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period","volume":"8","author":"Gomez-Reino","year":"2006","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.011_bib17","doi-asserted-by":"crossref","first-page":"R52","DOI":"10.1186\/ar2670","article-title":"Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British society of rheumatology biologics register","volume":"11","author":"Saad","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2014.10.011_bib18","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/annrheumdis-2013-204655","volume":"73","author":"Ritchlin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib19","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2013-204741","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.berh.2014.10.011_bib20","first-page":"S132","article-title":"Long-term (52-week) results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis (PALACE 2)","volume":"65","author":"Cutolo","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib21","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/annrheumdis-2013-205056","article-title":"Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor","volume":"73","author":"Kavanaugh","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"Suppl","key":"10.1016\/j.berh.2014.10.011_bib22","first-page":"S132","article-title":"Results of a phase 3, randomized, controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement (PALACE 3)","volume":"65","author":"Edwards","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"Suppl","key":"10.1016\/j.berh.2014.10.011_bib23","first-page":"L4","article-title":"Apremilast in the treatment of DMARD naive psoriatic arthritis patients: results of a phase 3, randomized, controlled trial (PALACE 4)","volume":"65","author":"Wells","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib24","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/rheumatology\/keg384","article-title":"A\u00a0prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience","volume":"42","author":"Kane","year":"2003","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib25","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1007\/s10067-007-0787-7","article-title":"The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate","volume":"27","author":"Scarpa","year":"2008","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib26","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1136\/ard.2011.150938","article-title":"Do patients with psoriatic arthritis who present early fare better than those presenting later in the disease?","volume":"70","author":"Gladman","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib27","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1136\/annrheumdis-2012-202608","article-title":"Smoking and delay to diagnosis are associated with poorer functional outcome in psoriatic arthritis","volume":"72","author":"Tillett","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib28","first-page":"10","article-title":"Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis","author":"Haroon","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib29","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/annrheumdis-2012-201972","article-title":"Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA)","volume":"73","author":"Theander","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1002\/art.38323","article-title":"Review: treat to target in rheumatoid arthritis: fact, fiction, or hypothesis?","volume":"66","author":"Solomon","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib31","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/annrheumdis-2013-203419","article-title":"Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force","volume":"73","author":"Smolen","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib32","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1136\/annrheumdis-2013-203860","article-title":"Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis","volume":"73","author":"Schoels","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib33","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/acr.20162","article-title":"Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res Hob )"},{"key":"10.1016\/j.berh.2014.10.011_bib34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/1471-2474-14-101","article-title":"The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis","volume":"14","author":"Coates","year":"2013","journal-title":"BMC Musculoskelet Disord"},{"key":"10.1016\/j.berh.2014.10.011_bib35","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/acr.20155","article-title":"Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data","volume":"62","author":"Coates","year":"2010","journal-title":"Arthritis Care Res Hob )"},{"key":"10.1016\/j.berh.2014.10.011_bib36","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s10067-014-2626-y","article-title":"Remission criteria and activity indices in psoriatic arthritis","volume":"33","author":"Acosta Felquer","year":"2014","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib37","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1136\/ard.2008.102053","article-title":"Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment","volume":"69","author":"Coates","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib38","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/keq078","article-title":"Evaluation of the treatment effect of NSAIDs\/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis","volume":"49","author":"Escalas","year":"2010","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib39","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1136\/annrheumdis-2012-201844","article-title":"NSAIDs and radiographic progression in ankylosing spondylitis bagging big game with small arms?","volume":"71","author":"Haroon","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib40","first-page":"10","article-title":"Evolution of radiographic damage in ankylosing spondylitis: a 12 year prospective follow-up of the OASIS study","author":"Ramiro","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib41","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1002\/art.21054","article-title":"Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial","volume":"52","author":"Wanders","year":"2005","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib42","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.1093\/rheumatology\/ker270","article-title":"Comparison of recommendations for the use of anti-tumour necrosis factor therapy in ankylosing spondylitis in 23 countries worldwide","volume":"50","author":"van den Berg","year":"2011","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib43","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1136\/ard.2011.151563","article-title":"2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis","volume":"70","author":"van der Heijde","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib44","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib45","first-page":"722","article-title":"Is sulfasalazine effective in ankylosing spondylitis? A systematic review of randomized controlled trials","volume":"33","author":"Chen","year":"2006","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib46","first-page":"CD004524","article-title":"Methotrexate for ankylosing spondylitis","volume":"2","author":"Chen","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.berh.2014.10.011_bib47","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/art.1780310905","article-title":"Sulfasalazine in the treatment of ankylosing spondylitis. A twenty-six-week, placebo-controlled clinical trial","volume":"31","author":"Nissila","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib48","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s00296-012-2619-6","article-title":"Non-biologic disease-modifying antirheumatic drugs (DMARDs) improve pain in inflammatory arthritis (IA): a systematic literature review of randomized controlled trials","volume":"33","author":"Steiman","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2014.10.011_bib49","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1002\/art.1780391209","article-title":"Comparison of sulfasalazine and placebo in the treatment of ankylosing spondylitis. A department of veterans affairs cooperative study","volume":"39","author":"Clegg","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib50","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ard.2003.019174","article-title":"Six months open label trial of leflunomide in active ankylosing spondylitis","volume":"64","author":"Haibel","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib51","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1007\/s00296-012-2571-5","article-title":"Thalidomide reduces recurrence of ankylosing spondylitis in patients following discontinuation of etanercept","volume":"33","author":"Deng","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2014.10.011_bib52","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/1529-0131(199904)42:3<580::AID-ANR27>3.0.CO;2-D","article-title":"Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis","volume":"42","author":"Breban","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1002\/art.10396","article-title":"One-year open-label trial of thalidomide in ankylosing spondylitis","volume":"47","author":"Huang","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib54","first-page":"2627","article-title":"Thalidomide for severe refractory ankylosing spondylitis: a 6-month open-label trial","volume":"30","author":"Wei","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib55","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/art.10139","article-title":"A\u00a0six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis","volume":"46","author":"Maksymowych","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib56","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/ard.2004.022871","article-title":"An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover","volume":"64","author":"Cairns","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib57","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1093\/rheumatology\/keg256","article-title":"Treatment of active ankylosing spondylitis with pamidronate","volume":"42","author":"Haibel","year":"2003","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib58","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1136\/ard.2005.041392","article-title":"Treatment of ankylosing spondylitis with pamidronate: an open label study","volume":"65","author":"Grover","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib59","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/rheumatology\/ket321","article-title":"Bisphosphonates vs infliximab in ankylosing spondylitis treatment","volume":"53","author":"Viapiana","year":"2014","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib60","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","article-title":"Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective","volume":"72","author":"Vincent","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib61","first-page":"10","article-title":"Efficacy of TNFalpha blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","author":"Callhoff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib62","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00296-013-2772-6","article-title":"Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis","volume":"33","author":"Machado","year":"2013","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.berh.2014.10.011_bib63","first-page":"1054","article-title":"Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents","volume":"15","author":"Gao","year":"2012","journal-title":"J\u00a0Med Econ"},{"key":"10.1016\/j.berh.2014.10.011_bib64","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/annrheumdis-2012-202698","article-title":"Continuous long-term anti-TNF therapy does not lead to an increase in the rate of new bone formation over 8 years in patients with ankylosing spondylitis","volume":"73","author":"Baraliakos","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib65","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/art.38070","article-title":"The impact of tumor necrosis factor alpha inhibitors on radiographic progression in ankylosing spondylitis","volume":"65","author":"Haroon","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib66","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1136\/ard.2005.040758","article-title":"First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis","volume":"65","author":"Braun","year":"2006","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib67","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib68","first-page":"561","article-title":"Ankylosing spondylitis: how diagnostic and therapeutic delay have changed over the last six decades","volume":"30","author":"Salvadorini","year":"2012","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib69","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/acr.21688","article-title":"Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis?","volume":"64","author":"Kiltz","year":"2012","journal-title":"Arthritis Care Res Hob )"},{"key":"10.1016\/j.berh.2014.10.011_bib70","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1136\/annrheumdis-2012-202073","article-title":"Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis","volume":"72","author":"Robinson","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib71","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/BOR.0b013e32835257c5","article-title":"Baseline predictors of response to TNF-alpha blocking therapy in ankylosing spondylitis","volume":"24","author":"Arends","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib72","doi-asserted-by":"crossref","unstructured":"Deodhar A, Reveille JD, van den Bosch F, et\u00a0al. The concept of axial Spondyloarthritis: joint statement of the Spondyloarthritis research and treatment network and the assessment of SpondyloArthritis international society in response to the US food and drug administration's comments and concerns. Arthritis Rheumatol Hoboken N. J 14 A.D.;66:2649\u20132656.","DOI":"10.1002\/art.38776"},{"key":"10.1016\/j.berh.2014.10.011_bib73","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1136\/annrheumdis-2014-205178","article-title":"Higher disease activity leads to more structural damage in the spine in ankylosing spondylitis: 12-year longitudinal data from the OASIS cohort","volume":"73","author":"Ramiro","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib74","first-page":"1356","article-title":"Canadian rheumatology association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis","volume":"30","author":"Maksymowych","year":"2003","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib75","first-page":"2273","article-title":"The Canadian rheumatology association\/spondyloarthritis research consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project","volume":"34","author":"Maksymowych","year":"2007","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib76","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.jbspin.2013.12.002","article-title":"Recommendations of the French Society for Rheumatology (SFR) on the everyday management of patients with spondyloarthritis","volume":"81","author":"Wendling","year":"2014","journal-title":"Jt Bone Spine"},{"key":"10.1016\/j.berh.2014.10.011_bib77","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaad.2008.02.040","article-title":"Guidelines of care for the management of psoriasis and psoriatic arthritis: section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics","volume":"58","author":"Gottlieb","year":"2008","journal-title":"J\u00a0Am Acad Dermatol"},{"key":"10.1016\/j.berh.2014.10.011_bib78","first-page":"S28","article-title":"Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian society for rheumatology","volume":"29","author":"Salvarani","year":"2011","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib79","first-page":"179","article-title":"Consensus statement of the Spanish society of rheumatology on the management of biologic therapies in psoriatic arthritis","volume":"7","author":"Fernandez Sueiro","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.berh.2014.10.011_bib80","first-page":"26","article-title":"2011 Portuguese recommendations for the use of biological therapies in patients with psoriatic arthritis","volume":"37","author":"Machado","year":"2012","journal-title":"Acta Reumatol Port"},{"key":"10.1016\/j.berh.2014.10.011_bib81","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/rheumatology\/ket187","article-title":"The 2012 BSR and BHPR guideline for the treatment of psoriatic arthritis with biologics","volume":"52","author":"Coates","year":"2013","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib82","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1136\/annrheumdis-2011-200350","article-title":"European league against rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies","volume":"71","author":"Gossec","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib83","unstructured":"NICE technology appraisal guidance 143. Adalimumab, etanercept and infliximab for ankylosing spondylitis. 2008."},{"key":"10.1016\/j.berh.2014.10.011_bib84","first-page":"784","article-title":"Evidence-based recommendations for the management of ankylosing spondylitis: results of the hellenic working group of the 3E initiative in Rheumatology","volume":"26","author":"Raptopoulou","year":"2008","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib85","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1093\/rheumatology\/kem348","article-title":"Evidence-based recommendations for the management of ankylosing spondylitis: systematic literature search of the 3E initiative in rheumatology involving a broad panel of experts and practising rheumatologists","volume":"47","author":"Sidiropoulos","year":"2008","journal-title":"Rheumatol Oxf"},{"key":"10.1016\/j.berh.2014.10.011_bib86","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.reuma.2010.12.002","article-title":"Consensus statement of the Spanish society of rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis","volume":"7","author":"Juanola Roura","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.berh.2014.10.011_bib87","first-page":"661","article-title":"The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis","volume":"28","author":"Arends","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib88","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1136\/ard.2007.072397","article-title":"Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation","volume":"66","author":"de Vries","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib89","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1136\/ard.2008.089979","article-title":"Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib90","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1136\/ard.2009.109702","article-title":"Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation","volume":"68","author":"de Vries","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib91","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial","volume":"63","author":"Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib92","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib93","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1136\/ard.2010.139261","article-title":"Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE)","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib94","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha","volume":"346","author":"Gorman","year":"2002","journal-title":"N.\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2014.10.011_bib95","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1111\/j.1756-185X.2012.01734.x","article-title":"Adalimumab significantly reduces inflammation and serum DKK-1 level but increases fatty deposition in lumbar spine in active ankylosing spondylitis","volume":"15","author":"Hu","year":"2012","journal-title":"Int J Rheumatic Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib96","series-title":"Efficacy and Safety of Adalimumab in Chinese Adults with Active Ankylosing Spondylitis: Results of a Randomised, Controlled Trial","author":"Huang","year":"2013"},{"key":"10.1016\/j.berh.2014.10.011_bib97","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.3899\/jrheum.091042","article-title":"A\u00a0double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis","volume":"37","author":"Inman","year":"2010","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2014.10.011_bib98","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.22097","article-title":"Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial","volume":"55","author":"van der Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.berh.2014.10.011_bib99","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1136\/ard.2010.139667","article-title":"Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial","volume":"70","author":"Song","year":"2011","journal-title":"Ann Rheumatic Dis"},{"key":"10.1016\/j.berh.2014.10.011_bib100","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1002\/art.38721","article-title":"Symptomatic efficacy of etanercept and its effects on objective signs of inflammation in early nonradiographic axial spondyloarthritis: a multicenter, randomized, double-blind, placebo-controlled trial","volume":"66","author":"Dougados","year":"2014","journal-title":"Arthritis Rheumatol Hoboken N. J"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169421400093X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S152169421400093X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,5]],"date-time":"2024-06-05T08:13:29Z","timestamp":1717575209000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S152169421400093X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":100,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S152169421400093X"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.011","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacologic treatment of psoriatic arthritis and axial spondyloarthritis with traditional biologic and non-biologic DMARDs","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2014.10.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}